Franklin Resources Inc. Has $10.73 Million Stock Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

Franklin Resources Inc. raised its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 10.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,466,062 shares of the company's stock after acquiring an additional 141,710 shares during the quarter. Franklin Resources Inc. owned approximately 2.31% of ABIVAX Société Anonyme worth $10,732,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ABVX. GAMMA Investing LLC bought a new position in ABIVAX Société Anonyme in the 4th quarter valued at approximately $29,000. R Squared Ltd bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at $36,000. BNP Paribas Financial Markets lifted its stake in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after acquiring an additional 5,900 shares during the last quarter. abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock valued at $3,105,000 after acquiring an additional 107,750 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in ABIVAX Société Anonyme during the 4th quarter worth $5,336,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABVX has been the topic of a number of recent research reports. Morgan Stanley reissued an "equal weight" rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $38.00.

ABIVAX Société Anonyme Trading Up 3.2 %

Shares of ABVX traded up $0.19 during trading hours on Monday, hitting $6.16. 23,036 shares of the stock were exchanged, compared to its average volume of 127,904. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $16.63. The business has a 50-day moving average of $6.71 and a 200-day moving average of $7.86.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.